人类偏肺病毒诊断市场－全球产业规模、份额、趋势、机会及预测（依技术、最终用途、地区及竞争格局划分，2021-2031年）

全球人类偏肺病毒诊断市场预计将从 2025 年的 6.1477 亿美元成长到 2031 年的 10.2876 亿美元，复合年增长率为 8.96%。

此细分市场包括用于鑑定呼吸道检检体中人类偏肺病毒（hMPV）抗原或RNA的专用试剂、检测方法和设备。市场发展的主要驱动因素是易感人群（包括婴幼儿和老年人）急性呼吸道感染疾病的日益普遍，以及临床上越来越多地采用多重检测来区分hMPV与流感病毒和呼吸道合胞病毒（RSV）。此外，透过准确检测病毒来改善患者照护并减少不合理使用抗生素的临床需求也推动了市场需求。

儘管存在这些有利因素，但先进分子诊断系统实施和营运成本高昂，为市场带来了重大障碍，阻碍了其在预算有限的医疗机构中的广泛应用。根据美国疾病管制与预防中心（CDC）的数据，2025年3月，美国人类偏肺病毒的全国检测阳性率为5.5%。如此高的病毒活性凸显了持续开发经济实惠的诊断方案以有效控制呼吸系统疾病影响的迫切需求。

市场驱动因素

多综合征检测组合的日益普及是市场成长的关键驱动力，它从根本上改变了临床诊疗方法，使其从单一病原体检测转向广泛的鑑别诊断。由于人类偏肺病毒（hMPV）相关的呼吸道症状通常与流感或呼吸道合胞病毒（RSV）的症状难以区分，医疗机构越来越依赖能够同时检测多个标靶的高通量分子检测系统。这一转变得益于强劲的产业表现。根据生物梅里埃公司于2025年3月发布的2024财年财务报告，BIOFIRE呼吸道检测组合的销售额成长了12%。这一趋势的驱动力源自于综合征检测持续的流行病学意义和重要的医疗效用。这些技术不仅能够提供快速、可操作的诊断数据，进而加速病患分诊，还能降低不必要的抗生素处方。

同时，人类偏肺病毒感染疾病的不断增加，凸显了对强大诊断能力的需求，尤其是在疫情过后，随着季节性感染模式逐渐恢復正常。该病毒对儿童和老年人的负担尤其沉重，因此需要在社区和医院环境中频繁进行检测，以控制疫情爆发。 2025年4月，美国疾病管制与预防中心（CDC）在题为《有症状人偏肺病毒感染的流行病学》的报告中指出，社区监测人群中，有症状的人偏肺病毒感染病例发生率为每年每百人7.5例。这种活跃的病毒活动直接推动了主要产业参与者检测量的增加。例如，丹纳赫公司在2025年报告称，其子公司Cefeed的呼吸系统诊断部门仅在2024年第四季就实现了约5.5亿美元的收入，这凸显了感染率所支撑的巨大市场规模。

市场挑战

全球人类偏肺病毒（hMPV）诊断市场扩张的主要障碍在于先进分子侦测系统相关的高昂资本和营运成本。儘管这些诊断平台具备准确识别hMPV所需的灵敏度，但其高昂的进入门槛对资金预算有限的医疗机构构成了重大阻碍。检查室经常面临两难：既要权衡广泛呼吸道病原体检测的临床获益，又要承担设备维护、专用试剂和人员培训等持续高昂成本。这种经济负担阻碍了分子检测在社区医院和门诊诊所的广泛应用，实际上将市场限制在资源雄厚的学术机构。

预算限制的影响因医疗服务成本的不断上涨而加剧，导致可用于实验室改进的自由支配资金减少。随着医疗机构营运成本的不断攀升，采购部门越来越多地推迟对昂贵诊断技术的投资，转而选择更经济的传统检测方案。根据美国医院协会预测，到2024年，医院总成本将成长5.1%，这一增幅远高于通膨率。以金额为准的经济压力迫使管理者实施严格的成本控制策略，并直接限制了临床实验室部署高通量分子检测系统的能力，而这些系统对于有效检测人类乳突病毒（hMPV）至关重要。

市场趋势

照护现场（POC）的广泛应用正在显着改变市场格局，将检测流程从集中式检查室转移到更贴近患者的场所。这种去中心化满足了小儿科和急诊护理环境中对快速检测结果的迫切需求，因为在这些环境中，立即检测出人类偏肺病毒（hMPV）对治疗方案和隔离通讯协定至关重要。为此，製造商正在推出紧凑、直觉的平台，这些平台能够在标准医院环境之外提供检查室层级的精准度，从而确保社区的诊断服务。这项基础诊断技术的持续需求也反映在近期的财务表现上。根据雅培公司于2024年10月发布的“2024财年第三季度财务业绩”，其全球诊断销售额（不包括新冠病毒检测）实现了3.3%的有机增长，表明公司核心诊断业务的稳健扩张。

同时，将人类偏肺病毒（hMPV）纳入呼吸道疾病监测计画正逐渐成为追踪季节性病毒波动的重要趋势。公共卫生机构日益重视将hMPV与流感病毒和呼吸道合胞病毒（RSV）一起纳入国家监测体系，以便更准确地预测疫情高峰并有效分配医疗资源。这种日益增长的关注源于呼吸道病毒大规模爆发后出现的不规则传播模式，因此需要全面的数据来指导疫苗监测和防治措施。近期流行病学统计数据也凸显了这种监测的必要性。根据Truveta公司2024年12月发布的《监测报告：呼吸道病毒－2024年11月资料》，2024年10月下旬至11月下旬，与人类偏肺病毒相关的住院人数激增172.7%，凸显了持续进行多病原体追踪机制的重要性。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球人类偏肺病毒诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依技术分类（基于PCR的诊断、次世代定序（NGS）、萤光、横向流动化验、微阵列技术、其他）
  • 依用途（医院/诊所、诊断/检测机构、学术/研究机构、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美人类偏肺病毒诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲人类偏肺病毒诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区人类偏肺病毒诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲人类偏肺病毒诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲人类偏肺病毒诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球人类偏肺病毒诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• QuidelOrtho Corporation
• ARUP Laboratories, Inc.
• DiaSorin SpA
• R-Biopharm AG
• Seegene Inc.
• ZeptoMetrix LLC
• Abbott Laboratories Inc.
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories, Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Human Metapneumovirus Diagnostics Market is projected to expand from USD 614.77 Million in 2025 to USD 1028.76 Million by 2031, registering a CAGR of 8.96 percent. This sector comprises the specialized reagents, assays, and instrumentation required to identify viral antigens or RNA of hMPV in respiratory samples. Market progression is primarily fueled by the rising prevalence of acute respiratory infections among susceptible populations, including infants and the elderly, as well as a growing clinical inclination toward multiplex testing panels that distinguish hMPV from Influenza and RSV. Additionally, the demand is bolstered by the clinical imperative to refine patient care and curtail inappropriate antibiotic administration through precise viral detection.

Despite these favorable drivers, the market encounters significant obstacles related to the substantial acquisition and operating expenses of sophisticated molecular diagnostic systems, which hinders their broad implementation in healthcare settings with limited budgets. Data from the Centers for Disease Control and Prevention indicated a national test positivity rate for human metapneumovirus of 5.5 percent in the United States during March 2025. This elevated level of viral activity highlights the enduring necessity for affordable diagnostic options to effectively manage the impact of respiratory diseases.

Market Driver

The increasing utilization of Multiplex Syndromic Testing Panels serves as a key catalyst for market growth, fundamentally transforming clinical approaches from single-pathogen testing to broad differential diagnosis. Because respiratory symptoms associated with hMPV are often indistinguishable from those of Influenza and RSV, medical providers are increasingly depending on high-throughput molecular systems capable of detecting multiple targets simultaneously. This shift is corroborated by robust industry performance; according to bioMerieux's '2024 Financial Results' released in March 2025, sales for BIOFIRE respiratory panels rose by 12 percent, a trend driven by the enduring epidemiology and significant medical utility of syndromic testing. These technologies not only accelerate patient triage but also reduce the likelihood of unneeded antibiotic prescriptions by providing quick and actionable diagnostic data.

Concurrently, the escalating incidence of Human Metapneumovirus infections is heightening the need for a strong diagnostic framework, especially as seasonal transmission patterns normalize following the pandemic. The virus places a substantial strain on pediatric and elderly groups, requiring frequent testing to control outbreaks in both community and hospital environments. In April 2025, the Centers for Disease Control and Prevention reported in the 'Epidemiology of Symptomatic Human Metapneumovirus Infection' that the incidence rate of symptomatic hMPV infection stood at 7.5 cases per 100 individuals annually within community surveillance groups. This intense viral activity directly supports high testing volumes for leading industry participants; for instance, Danaher Corporation reported in 2025 that its subsidiary Cepheid's respiratory diagnostics division achieved approximately 550 million dollars in revenue during the fourth quarter of 2024 alone, highlighting the significant market scale sustained by infection rates.

Market Challenge

A major obstacle impeding the expansion of the Global Human Metapneumovirus Diagnostics Market is the significant capital and operational expense linked to sophisticated molecular testing systems. Although these diagnostic platforms offer the sensitivity required for accurate hMPV identification, their steep acquisition prices present a formidable entry barrier for healthcare institutions operating with restricted capital budgets. Laboratories frequently face the difficult task of balancing the clinical advantages of extensive respiratory panels against the substantial recurring costs needed for equipment maintenance, specialized reagents, and staff training. This financial strain precludes the widespread implementation of molecular assays in community hospitals and outpatient clinics, effectively confining the market primarily to well-resourced academic centers.

The effect of these budgetary limitations is exacerbated by the increasing costs of healthcare delivery, which diminish the discretionary funds available for laboratory improvements. As healthcare organizations confront escalating operational overheads, procurement departments often postpone investments in high-end diagnostic technologies in favor of more economical, conventional testing options. According to the American Hospital Association, total hospital expenses rose by 5.1 percent in 2024, a rate significantly exceeding general inflation. This growing economic pressure compels administrators to enforce rigorous cost-control strategies, directly obstructing clinical laboratories' capacity to acquire the high-throughput molecular systems essential for effective hMPV detection.

Market Trends

The proliferation of Point-of-Care (POC) Molecular Diagnostics is significantly reshaping the market by moving testing procedures from centralized laboratories to near-patient environments. This decentralization fulfills the urgent requirement for rapid results in pediatric and urgent care settings, where the immediate detection of hMPV can decisively impact treatment plans and isolation protocols. In response, manufacturers are introducing compact, intuitive platforms that provide laboratory-grade accuracy outside of standard hospital settings, ensuring diagnostic availability in community locations. This ongoing demand for fundamental diagnostic technologies is reflected in recent financial outcomes; according to Abbott's 'Third-Quarter 2024 Results' published in October 2024, global diagnostic sales, excluding COVID-19 testing, grew by 3.3 percent on an organic basis, indicating robust expansion in the core diagnostic business.

Simultaneously, the incorporation of hMPV into Pan-Respiratory Surveillance Programs is developing as a crucial trend for tracking seasonal viral fluctuations. Public health organizations are increasingly prioritizing the addition of hMPV alongside Influenza and RSV in national monitoring efforts to more accurately forecast outbreak surges and deploy hospital resources effectively. This heightened focus is motivated by the erratic circulation patterns seen following widespread respiratory virus disruptions, necessitating comprehensive data to guide vaccination research and containment measures. The necessity of this surveillance is emphasized by recent epidemiological statistics; according to Truveta's December 2024 'Monitoring Report: Respiratory Viruses - November 2024 Data,' hospitalizations associated with human metapneumovirus surged by 172.7 percent between late October and late November 2024, highlighting the critical need for continuous, multi-pathogen tracking mechanisms.

Key Market Players

• QuidelOrtho Corporation
• ARUP Laboratories, Inc.
• DiaSorin S.p.A.
• R-Biopharm AG
• Seegene Inc.
• ZeptoMetrix LLC
• Abbott Laboratories Inc.
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories, Inc

Report Scope

In this report, the Global Human Metapneumovirus Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Metapneumovirus Diagnostics Market, By Technology

• PCR-based Diagnostics
• Next-generation Sequencing (NGS)
• Immunofluorescence Assays
• Lateral Flow Assays
• Microarray Technology
• Others

Human Metapneumovirus Diagnostics Market, By End Use

• Hospitals & Clinics
• Diagnostic & Reference Laboratories
• Academic & Research Institutions
• Others

Human Metapneumovirus Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human Metapneumovirus Diagnostics Market.

Available Customizations:

Global Human Metapneumovirus Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Human Metapneumovirus Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (PCR-based Diagnostics, Next-generation Sequencing (NGS), Immunofluorescence Assays, Lateral Flow Assays, Microarray Technology, Others)
  • 5.2.2. By End Use (Hospitals & Clinics, Diagnostic & Reference Laboratories, Academic & Research Institutions, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Human Metapneumovirus Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Human Metapneumovirus Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By End Use
  • 6.3.2. Canada Human Metapneumovirus Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By End Use
  • 6.3.3. Mexico Human Metapneumovirus Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By End Use

7. Europe Human Metapneumovirus Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Human Metapneumovirus Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By End Use
  • 7.3.2. France Human Metapneumovirus Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Human Metapneumovirus Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Human Metapneumovirus Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Human Metapneumovirus Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By End Use

8. Asia Pacific Human Metapneumovirus Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Human Metapneumovirus Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Human Metapneumovirus Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By End Use
  • 8.3.3. Japan Human Metapneumovirus Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By End Use
  • 8.3.4. South Korea Human Metapneumovirus Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Human Metapneumovirus Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By End Use

9. Middle East & Africa Human Metapneumovirus Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Human Metapneumovirus Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By End Use
  • 9.3.2. UAE Human Metapneumovirus Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By End Use
  • 9.3.3. South Africa Human Metapneumovirus Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By End Use

10. South America Human Metapneumovirus Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Human Metapneumovirus Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By End Use
  • 10.3.2. Colombia Human Metapneumovirus Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By End Use
  • 10.3.3. Argentina Human Metapneumovirus Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Human Metapneumovirus Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. QuidelOrtho Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ARUP Laboratories, Inc.
• 15.3. DiaSorin S.p.A.
• 15.4. R-Biopharm AG
• 15.5. Seegene Inc.
• 15.6. ZeptoMetrix LLC
• 15.7. Abbott Laboratories Inc.
• 15.8. Thermo Fisher Scientific Inc.
• 15.9. F. Hoffmann-La Roche Ltd.
• 15.10. Bio-Rad Laboratories, Inc

16. Strategic Recommendations

17. About Us & Disclaimer